Telix announces Cardinal Health as U.S. commercial distributor for Zircaix

Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET1 agent, Zircaix for the imaging of kidney cancer in the United States subject to regulatory approval. In preparation for a planned commercial rollout, Telix has contracted with Cardinal Health to enable Zircaix availability across a wide range of U.S. locations. Commencement of the distribution agreement between Telix and Cardinal Health is subject to regulatory approval and includes industry-standard commercial performance and termination conditions.